Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2020)

Monopar Therapeutics' Cash from Financing Activities history spans 4 years, with the latest figure at -$7140.0 for Q4 2020.

  • For Q4 2020, Cash from Financing Activities fell 100.08% year-over-year to -$7140.0; the TTM value through Dec 2020 reached $8.2 million, down 12.47%, while the annual FY2024 figure was $59.3 million, 2824.8% up from the prior year.
  • Cash from Financing Activities for Q4 2020 was -$7140.0 at Monopar Therapeutics, down from $6.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $9.4 million in Q4 2019 and bottomed at -$206270.0 in Q4 2018.
  • The 4-year median for Cash from Financing Activities is $508044.0 (2020), against an average of $2.1 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 2162.49% in 2018 before it soared 50810.13% in 2020.
  • A 4-year view of Cash from Financing Activities shows it stood at $10001.0 in 2017, then crashed by 2162.49% to -$206270.0 in 2018, then skyrocketed by 4650.77% to $9.4 million in 2019, then crashed by 100.08% to -$7140.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Cash from Financing Activities are -$7140.0 (Q4 2020), $6.7 million (Q3 2020), and $946404.0 (Q2 2020).